Topline data from the Phase III APPLAUSE-IgAN study showed that Novartis’ investigational complement inhibitor iptacopan met its pre-specified interim analysis primary endpoint, the company announced Monday.
Tag Archive for: irbesartan
The FDA is likely to push back the Prescription Drug User Fee Act target action date for Travere Therapeutics’ sparsentan by three months.